Medication info
Sitafolmin XR Extended-Release Tablet 50/500 mg

Sitafolmin XR Extended-Release Tablet 50/500 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tablet
Manufacturer / importer
Jongkundang Co., Ltd.
Appearance
Pale blue, bilaterally convex, oval-shaped extended-release film-coated tablets
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201600365 · Approved 2016.01.20 · Insurance code 643307390

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and should not be split, crushed, ground, or chewed. Cases have been reported in which the medicine was not completely dissolved and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin treatment: For patients who have not previously received antidiabetic drug therapy and whose blood glucose cannot be adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 100 mg and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. - Patients previously receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily may start with this medicine 50/1000 mg extended-release tablets, 2 tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Ingredients

Manufacturer
Jongkundang Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood glucose control
  • type 2 diabetes
View approved original text

This medication is used to improve blood glucose control in adults with type 2 diabetes, in conjunction with dietary and exercise regimens. It is particularly effective in cases where prior diabetes medication treatment has not been administered and achieving blood glucose control with monotherapy is challenging. Additionally, it may be used when blood glucose levels are insufficiently controlled with monotherapies of metformin or sitagliptin, or as an alternative to the combination therapy of these two medications. Furthermore, if blood glucose control is inadequate with combinations of metformin and sulfonylureas, or metformin and thiazolidinediones, this medication can be used in conjunction. Lastly, it assists in blood glucose control as an adjunct when insulin and metformin combination therapy is insufficient. It aids in improving blood glucose control across various treatment scenarios.

How to take

Adult dose

In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine should be taken once daily with a meal, preferably in the evening, to reduce gastrointestinal adverse reactions caused by metformin, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and should not be split, crushed, ground, or chewed. Cases have been reported in which the medicine was not completely dissolved and was excreted in the stool. It is not known whether the material excreted in the stool contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the stool, healthcare professionals should assess whether blood glucose is being adequately controlled (see Precautions, 5. General Precautions). Take 1 tablet of this medicine 100/1000 mg extended-release tablet once daily. Patients taking this medicine 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin treatment: For patients who have not previously received antidiabetic drug therapy and whose blood glucose cannot be adequately controlled with monotherapy, or for whom adequate blood glucose control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate blood glucose control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions, 2. Do not administer to the following patients). 2. Patients receiving metformin treatment: - For patients whose blood glucose cannot be adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 100 mg and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. - Patients previously receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily may start with this medicine 50/1000 mg extended-release tablets, 2 tablets once daily. 3. Patients whose blood glucose cannot be adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and existing dose. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions, 2. Do not administer to the following patients).

Precautions

This medication contains sitagliptin and metformin as active ingredients and helps in blood glucose control. Severe allergic reactions may occur while taking this medication; therefore, if symptoms such as hives, rash, difficulty breathing, or swelling of the face or neck appear, discontinue the medication immediately and consult a doctor. Serious side effects such as acute pancreatitis, which involves inflammation of the pancreas, have been reported. If symptoms such as abdominal pain, vomiting, nausea, or fever occur, inform a medical professional right away. This medication should not be administered to patients with significantly impaired kidney function, severe infections or dehydration, heart failure, acute myocardial infarction, or septic conditions. Additionally, if undergoing exams involving radiographic contrast agents, the medication should be discontinued for a certain period before and after the examination, and it should be resumed only after normal kidney function has been confirmed. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. As this medication may cause hypoglycemia, especially when taken with insulin or sulfonylureas, blood glucose levels should be monitored carefully. Due to the metformin component, there is a rare but serious risk of lactic acidosis; if symptoms such as fatigue, muscle pain, difficulty breathing, or abdominal pain occur, visit a healthcare facility immediately. Regular monitoring of kidney function, blood tests, and vitamin B12 levels during treatment is important. Alcohol consumption can increase the risk of lactic acidosis; thus, it is advisable to avoid drinking alcohol while on this medication. If undergoing surgery, discontinue this medication 48 hours before the procedure and resume it only after the patient’s condition stabilizes and kidney function is confirmed to be normal. Safety and efficacy have not been established for children and adolescents under 18 years of age; therefore, it should not be used in these populations. Elderly patients may experience reduced kidney function, so kidney function should be monitored regularly, and dosage adjustments should be made as necessary. In case of an overdose, seek medical attention immediately, as some of the medication may be removed through blood dialysis. Regular blood glucose monitoring and consistent adherence to diet and exercise regimens are important while taking this medication.

Side effects

  • Severe hypersensitivity reactions
  • anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory infection
  • headache
Show 17 more
  • nausea
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • arthralgia with severity and disability
  • bullous pemphigoid
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rash
  • urticaria
  • cutaneous vasculitis
  • acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. Store at room temperature between 1 °C and 30 °C. This will help maintain its effectiveness.

Appearance and packaging

Appearance

Pale blue, bilaterally convex, oval-shaped extended-release film-coated tablets

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.